Pilot Study for the Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 Patients Using Topical Sirolimus Gel

Published: 19 August 2022| Version 1 | DOI: 10.17632/b3ycg7sshg.1
Contributor:
Mari Wataya-Kaneda

Description

In this reports we showed the results of "Pilot Study for the Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 Patients Using Topical Sirolimus Gel." Sirolimus gel might become a promising treatment for cutaneous neurofibromas, a disease with no effective therapies.

Files

Steps to reproduce

A double-blind, randomized, placebo-controlled, parallel-group, pilot study of 0%, 0.2% and 0.4% sirolimus gels included 18 patients (9 men, 9 women) between 27–68 years of age (median 45 years) who were definitively diagnosed with NF1 according to the diagnostic criteria in Japan and was conducted from March 16, 2016–January 11, 2017.

Institutions

Osaka Daigaku

Categories

Clinical Trial, Sirolimus, Mammalian Target of Rapamycin, Neurofibromatosis, Pilot Study, Topical Treatment

License